The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Ferrars & York is a six-storey, 22-unit, carbon-neutral apartment building in South Melbourne, just 100 metres from the South Melbourne Market. Its sawtooth roof and industrial materials reference the ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

Among those with a chronic condition, concern of getting shingles is low with only 12% highly concerned and 37% somewhat concerned Over 80% of those with a chronic condition have not been informed by ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.